GlaxoSmithKline: The Events That Never Happened

In the GlaxoSmithKline FCPA case, the company agreed to pay a $20 million civil penalty in 2016 to settle Securities and Exchange Commission charges that false accounting and failed controls concealed pay-to-prescribe schemes in China. The commission alleged that payments to health care professionals ran through travel invoices, speaker fees and marketing expenses. If you worked with those budgets, approved the reimbursements or questioned the events, this case shows how ordinary sales paperwork can reveal what the company was buying.

The SEC’s September 30 order addressed GlaxoSmithKline plc, the British pharmaceutical company whose stock traded on the New York Stock Exchange. This FCPA settlement arose under the Foreign Corrupt Practices Act and concerned the company’s books and records and internal accounting controls, with allegations about its China sales subsidiary and a Chinese joint venture.

Prescriptions Written Into the Sales Plan

The SEC alleged that employees and agents paid health care professionals to increase prescriptions and hospital administrative staff to influence product selection and purchases. Its order described conduct from at least 2010 to June 2013, across the China operations’ sales and marketing functions and product lines. Regional and district managers condoned the practices, according to the order.

The sales representative’s work plan described in the order made the alleged exchange unusually plain. Submitted to a regional sales manager in 2013, it described paying a healthcare professional RMB 20 for each box prescribed every month, with holiday gifts in exchange for more than 40 boxes of prescriptions a month. The intended benefit and the expected sales were in the same plan.

This is why pharmaceutical bribery reaches beyond the purchasing office. In the 2015 SEC speech FCPA, Disclosure, and Internal Controls Issues Arising in the Pharmaceutical Industry, the enforcement director explained that doctors, pharmacists and administrators at foreign public hospitals often decide which products their institutions buy and can qualify as foreign officials. A prescription or product-selection decision can direct public health spending toward the company paying for it.

The Securities and Exchange Commission’s GSK announcement tied the pay-to-prescribe schemes to millions of dollars in increased sales to China’s state health institutions. That is the commercial connection an insider may know firsthand: which professional could move the business, what benefit the sales team offered, and how the team expected to measure the return.

The Travel Invoice Supplied the Cash

The SEC alleged that employees used cooperating outside vendors to fund improper payments, including vendors arranging travel and events for healthcare professionals. According to the order, GSK’s China sales subsidiary spent nearly $225 million on planning and travel services during the period it covered. The invoice sample showed:

We compare the vendor’s bill with the event and expense records behind it. An invoice can look complete while the event it describes never took place.

The order also described gifts, shopping excursions, family and home visits, cash, and travel or entertainment with little or no educational purpose. According to the SEC, the costs appeared in the books as medical-association sponsorships, employee expenses, conferences, speaker fees and marketing costs. In that account, the supposed business expense supplied both the money and its explanation.

Speaker Limits Without Verified Speakers

The SEC alleged that GSK limited speaker fees without an effective system for checking the speaker’s actual identity. The policies limited hourly fees by 2010 and cumulative annual fees by 2012. The order said that of approximately $17 million spent on speaker fees, approximately $2.2 million went to people whose qualification as a health care professional could not be verified.

We see the absurdity in that comparison: a company can police the price of a speech while failing to establish who supposedly gave it. For someone handling speaker engagements or payments, the identity and qualifications behind the fee matter as much as whether the amount fits the budget.

A Vaccine Project Became an Electronics Giveaway

The SEC alleged that GSK’s Cold Chain Project became another way to influence healthcare professionals. Launched through a local vendor in 2010, the project was intended to give clinics tools for storing and administering vaccines that required refrigeration. Instead, the order said, it supplied gifts including laptops, tablets and other electronic devices.

According to the order, GSK’s China subsidiary paid approximately $2.3 million over the project’s life. It said senior marketing and sales managers created and administered the project, selecting clinics for their potential to buy additional pharmaceutical products. As the SEC described it, a program presented as support for vaccine delivery was being directed by the opportunity to sell more medicine.

For an employee who knew the project, the useful connection would be between its stated purpose, what the vendor actually supplied, and why particular clinics were chosen. The SEC’s account puts those decisions inside sales and marketing management.

The Audit Had Already Found the Warning Signs

The Securities and Exchange Commission’s order put the failure in the response to the audit findings:

The SEC described a 2013 internal audit of the Guangzhou sales office that identified fake bank statements and fake hotel and restaurant invoices for sales meetings. According to the order, the invoices came from a preferred local meeting agency, and the audit flagged commission-driven pay as a possible incentive to inflate sales.

The order traced warnings back to a 2010 internal audit. That audit, the SEC said, identified approvals of noncompliant activities and documentation that failed to support the legitimate purpose of advisory boards and meeting sponsorships.

For an auditor or compliance employee, the response to a finding can be as revealing as the finding itself. Here, the SEC alleged that the business treated paperwork its auditors called fake as disconnected incidents. We would want to understand who saw the findings, how management explained them, and what changed afterward.

What the Books Called the Payments

The Securities and Exchange Commission resolved GSK’s case under the Foreign Corrupt Practices Act’s books-and-records and internal accounting controls provisions. The order connected the improper benefits to ordinary expense categories and to failures in vendor oversight, speaker verification and the response to audit findings.

The transaction has several connected parts: the healthcare professional’s decision, the benefit, the vendor or employee expense, the accounting description, and the manager who approved it. An invoice reviewer may see an inflated bill while a sales employee knows the prescription target it was meant to support. Together, those accounts can explain why the payment was made and why its description concealed the purpose.

The order also alleged that the same weaknesses in accounting controls and compliance led to similar conduct in other countries where GSK operated. Its China examples show the links between sales, vendors and false expenses that an insider in another market may recognize.

The Same Prescription Incentive in Other Cases

Novartis Hellas offers a close comparison between benefits and expected prescriptions. In its 2020 Novartis order, the SEC alleged that Greek ophthalmology staff ranked healthcare professionals by prescribing preference and volume, treated benefits as investments, and reduced or stopped those benefits when the prescription return disappointed. As described in the orders, GSK’s work plan and the Novartis planning documents both made the desired commercial return visible inside the sales operation.

The Fresenius Medical Care case shows what could happen to the wording after a similar incentive entered the accounts. The SEC alleged that its China clinic business provided bonuses to publicly employed healthcare professionals, with amounts based partly on treatments and new patients. Emails suggested that the payments were intended to influence procurement decisions, and the order described a manager’s response to the accounting language:

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA identifies managers and employees circumventing controls despite flagged transactions and existing policies. That study’s observation helps explain why an audit finding deserves to be read alongside the response to it. The SEC’s allegations against GSK supply its particular version of the problem: warnings existed, but the larger pattern went unaddressed.

What an Insider Can Connect

The most useful evidence of the payment’s purpose connects records that may look ordinary on their own. In GSK’s case, the SEC described a sales plan tying payments to prescription volume, event invoices that failed testing, speaker payments without verified qualifications, and audits identifying false documentation. Each tells a different part of the commercial story.

A sales employee may understand the promised prescription return. A finance employee may know how the expense entered the books, while an event or vendor employee may know whether the service happened at all. We work with that firsthand knowledge to connect the sales objective, the payment and the people who approved or questioned it.

What Money Determines the Reward?

The SEC whistleblower program can pay eligible whistleblowers 10% to 30% of money collected in a successful enforcement case and qualifying related cases. The SEC case must result in an order to pay more than $1 million. Our whistleblower experts assess how your information connects to the transactions and the potential reward.

The False Claims Act is a separate program for fraud against the U.S. government, under which a whistleblower case can pay 15% to 30% of what the government recovers. GSK’s China accounting settlement was an SEC action under the Foreign Corrupt Practices Act. We match your knowledge to the program and pharmaceutical bribery whistleblower lawyers who can pursue your case.

You Know What the Expense Was For

If you know which prescriptions a speaker fee was meant to buy, or why an event invoice never matched an event, talk with our whistleblower experts. We build your strongest case with you, bring in pharmaceutical bribery whistleblower lawyers who understand sales incentives and accounting evidence, and stay beside you through the pursuit of a recovery.